discovery system that integrates optimized sample preparation, LC-MS/MS, and statistical analysis to identify biologically significant plasma peptides and proteins. It also provides ELiMSA, a measurement technology that combines enzyme amplification with LC-MS/MS to quantitatively assay circulating proteins, peptides, cell-surface receptors, and nucleic acids. These platforms support applications such as diagnostic and prognostic marker discovery, therapeutic target identification, protein modification analysis, patient stratification, and high-throughput screening of biologics. YYZ Pharmatech collaborates with life science organizations seeking to apply plasma proteomics to oncology, immunology, metabolic disorders, and other disease areas.